1. Show article details.

    Theravance to Report First Quarter 2014 Financial Results on May 6, 2014

    Market Wire – 4:05 PM ET 04/15/2014

    04/15/14 -- Theravance, Inc. (THRX) announced today that it will release financial results for the period ended March 31, 2014 after market close on Tuesday, May 6, 2014. An accompanying conference call will be held at 5:00 p.m. Eastern Daylight Time. A replay of the conference call will be available on Theravance's (THRX) web site for 30 days through June 5, 2014.

  2. Show article details.

    Theravance Announces Initiation of Phase 2b Study With TD-4208, an Investigational LAMA for the Treatment of COPD

    Market Wire – 4:05 PM ET 04/10/2014

    04/10/14 -- Theravance, Inc. (THRX) announced the initiation of the dose-ranging Phase 2b Study 0117 with TD-4208 as a nebulized aqueous solution in patients with moderate to severe chronic obstructive pulmonary disease. "We are very pleased with the progression of TD-4208 into a Phase 2b study in patients with COPD," said Mathai Mammen, M.D., Ph.D., Senior Vice President of Research and Development.

  3. Show article details.

    Biotech Stocks Coverage -- Research on Seattle Genetics, Theravance, Neurocrine Biosciences, and MiMedx

    PR Newswire – 12:30 PM ET 04/10/2014

    LONDON, April 10, 2014 On Wednesday, April 09, 2014, the NASDAQ Composite ended at 4,183.90, up 1.72%, the Dow Jones Industrial Average advanced 1.11% to 16,437.18, and the S&P 500 closed at 1,872.18, up 1.09%. The gains were broad based as eight out of 10 sectors ended the session in positive. SOURCE Investor-Edge.

  4. Show article details.

    Healthcare Companies Announce Awards, Partnerships, Milestone Payments, and Conference Schedules - Analyst Notes on Inovio, LifePoint, Mallinckrodt, Ligand, and Theravance

    PR Newswire – 8:00 AM ET 04/02/2014

    NEW YORK, April 2, 2014 Today, Analysts Review released its analysts' notes regarding Inovio Pharmaceuticals, Inc., LifePoint Hospitals Inc. (LPNT), Mallinckrodt (MNK) plc, Ligand Pharmaceuticals Incorporated (LGND), and Theravance Inc. (THRX). Private wealth members receive these notes ahead of publication.

  5. Show article details.

    Theravance Appoints Kevin Kwok, Head of Talent Acquisition and Strategy

    Market Wire – 4:05 PM ET 04/01/2014

    04/01/14 -- Theravance, Inc. (THRX) announced today the appointment of Kevin Kwok as Head of Talent Acquisition and Strategy. Dr. Kwok joins Theravance (THRX) from Russell Reynolds Associates, where he served as Managing Director, Head of North American Life Science Practice.

  6. Show article details.

    Theravance to Present at the 13th Annual Needham Healthcare Conference

    Market Wire – 4:05 PM ET 03/26/2014

    03/26/14 -- Theravance, Inc. (THRX) announced today that Michael W. Aguiar, Theravance's Senior Vice President and Chief Financial Officer, is scheduled to present at the 13th Annual Needham Healthcare Conference on Wednesday, April 9, 2014, at 9:20 a.m. EDT.

  7. Show article details.

    GlaxoSmithKline Studies on Lung Disease Drug Show Positive Results -- Update

    DJ Business News – 9:46 AM ET 03/14/2014

    LONDON--U.K. pharmaceuticals giant GlaxoSmithKline PLC Friday said three late-stage studies into a lung disease drug it developed with San Francisco-based Theravance Inc. (THRX) produced positive results. Anoro Ellipta is a treatment for chronic obstructive pulmonary disease, or COPD, a condition typically brought on by smoking which affects nearly 27 million people in the U.S. according to the National Heart, Lung and Blood Institute. The "phase three" studies showed patients...

  8. Show article details.

    GSK Studies on Lung Disease Drug Show Positive Results

    DJ Business News – 8:46 AM ET 03/14/2014

    LONDON--U.K. pharmaceuticals giant GlaxoSmithKline PLC (GSK) said Friday that three late-stage studies into a lung disease drug it developed with San Francisco-based Theravance Inc. (THRX) produced positive results. Anoro Ellipta is a treatment for chronic obstructive pulmonary disease, or COPD, a condition typically brought on by smoking which affects nearly 27 million people in the U.S., according to the National Heart, Lung and Blood Institute. The "phase-three" studies showed...

  9. Show article details.

    GSK and Theravance Announce Positive Results From Studies Comparing ANORO(TM) ELLIPTA(TM) With SERETIDE(R) DISKUS(R) and ADVAIR(R) DISKUS(R) in Patients With COPD

    Market Wire – 8:00 AM ET 03/14/2014

    03/14/14 -- GlaxoSmithKline plc (GSK) and Theravance, Inc. (THRX) today announced positive results from three phase III studies. In each of the studies UMEC/VI achieved a statistically significant improvement in lung function, measured as weighted mean forced expiratory volume in one second over 0-24 hours at the end of the 12 week study, compared to either dose of FSC.

  10. Show article details.

    Patient Recruitment Completes in Landmark RELVAR(R)/BREO(R) ELLIPTA(R) Study to Understand Mortality and MorbidITy (SUMMIT) in COPD

    Market Wire – 8:00 AM ET 03/13/2014

    03/13/14 -- GlaxoSmithKline plc (GSK) and Theravance, Inc. (THRX) today announced that recruitment of patients into the "Study to Understand Mortality and MorbidITy", known as SUMMIT, has completed enrolment.

  11. Show article details.

    Financial Results, Clinical Study Updates, Clinical Trial Results, Business Spin-Offs, and New Joint Ventures - Analyst Notes on ARIAD, NewLink, Puma Biotechnology, Theravance, and Ohr Pharmaceutical

    PR Newswire – 8:00 AM ET 03/12/2014

    NEW YORK, March 12, 2014 Today, Analysts Review released its analysts' notes regarding ARIAD Pharmaceuticals, Inc. (ARIA), NewLink Genetics Corporation (NLNK), Puma Biotechnology, Inc. (PBYI), Theravance, Inc. (THRX), and Ohr Pharmaceutical, Inc. (OHRP). Private wealth members receive these notes ahead of publication. -- ARIAD Pharmaceuticals, Inc. Analyst Notes.

  12. Show article details.

    Theravance Announces Update to Planned Separation of Late-Stage Partnered Respiratory Assets from Biopharmaceutical Operations

    Market Wire – 4:55 PM ET 03/03/2014

    03/03/14 -- Theravance, Inc. (THRX) announced today that its plan to separate its businesses into two independent, publicly traded companies is now expected to be completed during the second quarter 2014.

  13. Show article details.

    Theravance to Present at Investor Conferences in March 2014

    Market Wire – 4:05 PM ET 02/25/2014

    02/25/14 -- Theravance, Inc. (THRX) announced today that Theravance (THRX) management is scheduled to present at the following investor conferences in March 2014: Cowen and Company 34th Annual Health Care Conference The Boston Marriott Copley Place, Boston, MA Wednesday, March 5, 2014 10:00 a.m. ET Rick E Winningham, Chief Executive Officer.

  14. Show article details.

    EU Agency backs respiratory drugs for approval

    Reuters – 9:14 AM ET 02/21/2014

    European regulators recommended the approval of a clutch of drugs to treat respiratory diseases on Friday, including two from GlaxoSmithKline and another from Teva Pharmaceuticals.

  15. Show article details.

    GSK receives European nod for COPD drugs Anoro, Incruse

    Reuters – 5:02 PM ET 02/20/2014

    Anoro, a combination drug for chronic obstructive pulmonary disease developed by GlaxoSmithKline and Theravance (THRX), has received the green light from European regulators, the companies said on Thursday. The medicine is a combination of umeclidinium, a long-acting muscarinic antagonist that helps lung function, and vilanterol, a long-acting beta agonist that opens the airways, in a single inhaler.

  16. Show article details.

    GlaxoSmithKline: European Medicines Agency Recommends Anoro

    DJ Business News – 8:14 AM ET 02/20/2014

    LONDON--U.K. drug company GlaxoSmithKline PLC (GSK) and Theravance Inc. Thursday said a European Union agency recommended that their new treatment for lung disease be approved for sale. The European Medicines Agency's Committee for Medicinal Products for Human Use recommended marketing authorization for Anoro, a drug for people with chronic obstructive pulmonary disease, or COPD, GSK said in a statement with San Francisco-based Theravance (THRX). "COPD affects millions of people...

  17. Show article details.

    GlaxoSmithKline's COPD drug Anoro receives European green light

    Reuters – 8:12 AM ET 02/20/2014

    Anoro, a combination drug for chronic obstructive pulmonary disease developed by GlaxoSmithKline and Theravance (THRX), has received the green light from European regulators, the companies said on Thursday. The drug is a combination of UMEC, a long-acting muscarinic antagonist, and VI, a long-acting beta agonist, in a single inhaler.

  18. Show article details.

    Anoro(R) (umeclidinium / vilanterol) Receives Positive Opinion From the CHMP in Europe for the Treatment of COPD

    Market Wire – 7:58 AM ET 02/20/2014

    02/20/14 -- GlaxoSmithKline plc (GSK) and Theravance, Inc. (THRX) today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has issued a positive opinion recommending marketing authorisation for umeclidinium/vilanterol under the proposed brand name Anoro® as a once-daily, maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstru...

  19. Show article details.

    Theravance Reports 2013 Financial Results

    Market Wire – 4:09 PM ET 02/06/2014

    02/06/14 -- Theravance, Inc. (THRX) reported today its financial results for the fourth quarter and full year ended December 31, 2013.

  20. Show article details.

    Theravance to Present at the Leerink Global Healthcare Conference

    Market Wire – 4:05 PM ET 01/30/2014

    01/30/14 -- Theravance, Inc. (THRX) announced today that Michael W. Aguiar, Theravance's Senior Vice President and Chief Financial Officer, is scheduled to present at the Leerink Global Healthcare Conference on Thursday, February 13, 2014, at 8:30 a.m. EST.

Page:

Today's and Upcoming Events

  • May
    6

    THRX to announce Q1 earnings After Market (Confirmed)

  • May
    6

    THRX Earnings Conference Call at 5:00 PM Listen

  • May
    22

    Shareholders Meeting

Past Events (last 90 days)

No events in the past 90 days

Data provided by Wall Street Horizon, Inc. © 2014

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.